|
|---|
| Completed | | Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV Infection
Condition: HIV Infections | | En español |
|
| Terminated | | Effects of Immunization With HIV-1 Immunogen Plus Anti-HIV Treatment Interruption on the Levels of HIV
Condition: HIV Infections | | En español |
|
| Completed | | Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV
Condition: HIV Infections | | En español |
|
| Completed | | Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452
Condition: HIV Infections | | En español |
|
| Completed | | Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination
Condition: HIV Infections | | En español |
|
| Completed | | Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination
Condition: HIV Infections | | En español |
|
| Terminated | | Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination
Condition: HIV Infections | | En español |
|
| Completed | | A Study to Monitor the Health of Participants in HIVNET 014 Who Become Infected With HIV-1
Condition: HIV Infections | | En español |
|
| Completed | | Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug Therapy
Condition: HIV Infections | | En español |
|
| Completed | | A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328
Condition: HIV Infections | | En español |
|
| Terminated | | Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)
Condition: HIV Infections; Pregnancy; HIV Seronegativity | | |
|
| Completed | | A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3
Condition: HIV Infections | | |
|
| Completed | | A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)
Condition: HIV Infections | | |
|
| Completed | | A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells
Condition: HIV Infections | | |
|
| Terminated | | Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women
Condition: HIV Infections; HIV Seronegativity | | |
|
| Completed | | Phase I Safety and Immunogenicity Vaccine Trial Against HIV/AIDS
Condition: HIV Infections | | |
|
| Completed | | Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)
Condition: HIV Infections; Pregnancy | | |
|
| Completed | | Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients
Condition: HIV Infections | | |
|
| Completed | | A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals
Condition: HIV Infections | | |
|
| Completed | | A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3
Condition: HIV Infections | | |
|
| Completed | | Analysis of Immune Responses to HIV Vaccines
Condition: Acquired Immunodeficiency Syndrome; HIV Infections | | |
|
| Completed | | Active Immunization of Asymptomatic, HIV-Infected Individuals With Recombinant GP160 HIV-1 Antigen: A Phase I/II Study of Immunogenicity and Toxicity
Condition: HIV Infections | | |
|
| Completed | | Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV
Condition: HIV Infections | | |
|
| Completed | | Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients
Condition: HIV Infections | | |
|
| Completed | | A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen
Condition: HIV Infections | | |
|
| Completed | | Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)
Condition: HIV Infections; Pregnancy; HIV Seronegativity | | |
|
| Completed | | A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection
Condition: HIV Infections | | |
|
| Completed | | A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons
Condition: HIV Infections | | |
|
| Completed | | HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs
Condition: HIV Infections | | |
|
| Completed | | A Randomized Controlled Trial of a Mindfulness-Based Stress Reduction Intervention for Men Living With HIV
Condition: HIV Infections | | |
|
| Completed | | A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells
Condition: HIV Infections | | |
|
| Completed | | Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load
Condition: HIV Infections | | |
|